Good news for those patients suffering from advanced stomach cancer or gastroesophageal junction adenocarcinoma (a type of cancer located at the junction of stomach and esophagus) as Cyramza (ramucirumab) has been approved by U.S Food and Drug Administration (FDA) to treat such patients.
Stomach cancer mainly targets older adults. It has been estimated that nearly 22,220 patients will be diagnosed and 10,990 patients will loose their lives due to stomach cancer in 2014 in United State.
Mode of Action of Cyramza:
Cyramza is a drug that inhibits the process of angiogenesis which provides blood supply to cancerous cells. This will be considered as a drug of choice for those patients whose tumor has spread in different organs (malignant tumor) and have undergone fluoropyrimidine- or platinum-containing therapy or for those whose tumor cannot be removed after surgery.
“Although the rates of stomach cancer in the United States have decreased over the past 40 years, patients require new treatment options, particularly when they no longer respond to other therapies,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Cyramza is new treatment option that has demonstrated an ability to extend patients’ lives and slow tumor growth.”
Safety and Efficacy:
FDA evaluated the safety and effectiveness of Cyramza during a trial in which 355 patients suffering from stomach cancer of either metastatic or unresectable. The overall survival rate was significantly higher in patients those who received Cyramza when compared with those who were given placebo.
Some common and predictable side effects associated with the use of Cyramza are as following;
- Hypertension (high blood pressure)
Cyramza is being marketed by Indianapolis-based Eli Lilly..
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.